Lenvatinib, una nueva primera línea en carcinoma hepatocelular: estudio REFLECT

Kudo M

et al

Lancet

. 2018;pii:S0140-6736(18)30207–1

REFLECT TRIAL: Study Drug Administration

Parameter

Lenvatinib

Sorafenib

Median duration of treatment

5.7 months

3.7 months

Mean dose intensity

7.0 mg

for 8 mg/day dose

10.5 mg

for 12 mg/day dose

663.8 mg

for 400 mg BID dose (800 mg/day)

Percentage of planned starting dose

88%

83.0%

BID = bis in die [twice a day].